NCT07503197Enrolling by invitation
A Study on the Efficacy of 2% Cholesterol Cream in Atopic Dermatitis
A Pilot Study on the Efficacy of 2% Cholesterol Cream in Preventing Transepidermal Water Loss and Clinical Symptoms in Mild to Moderate Atopic Dermatitis.
Source: ClinicalTrials.gov · Last updated 14 May 2026
Brief summary (registry, in English)
Atopic dermatitis is a common chronic inflammatory skin condition characterized by impaired skin barrier function, leading to increased transepidermal water loss (TEWL), dry skin, and itching. Restoration of the skin barrier is an important component of treatment. Cholesterol is a key lipid in the stratum corneum that plays a role in maintaining skin barrier integrity. This study aims to evaluate the efficacy and safety of 2% cholesterol cream in improving skin barrier function and clinical symptoms in patients with mild to moderate atopic dermatitis aged 7-17 years. Participants will be randomly assigned to receive either 2% cholesterol cream or a placebo (cream base), applied twice daily for 12 weeks. Outcomes will include measurements of transepidermal water loss (TEWL), skin hydration, skin pH, Investigator's Global Assessment (IGA), Eczema Area and Severity Index (EASI), and pruritus numeric rating scale (NRS). The results of this study may support the use of cholesterol-containing topical formulations as a safe and effective treatment option for atopic dermatitis.
- Status (registry)
- Enrolling by invitation
- Study type
- Interventional
- Enrollment
- 30 (estimated)
- First submitted
- 25 Mar 2026
- Start date
- 1 Apr 2026
- Primary completion date
- 12 Dec 2026
- Lead sponsor
- Institute of Dermatology, Thailand
- Diseases
- Atopic dermatitis (eczema)
- NCT number
- NCT07503197
What you commit to
- Study type: Interventional
- Planned participants: 30
- From 1 Apr 2026 to the primary completion date, 12 Dec 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Use of systemic immunosuppressive therapy (e.g., prednisolone, dupilumab, JAK inhibitors)
Other illness
- Presence of other dermatologic conditions other than atopic dermatitis
- History of chronic infections such as hepatitis B, hepatitis C, herpes zoster, or tuberculosis
- History of any malignancy
Other
- Pregnant or breastfeeding women, or those planning pregnancy during the study period
Who the study is looking for
- Thai nationality
- Aged between 7-17 years
- Able to read and write Thai fluently
- Clinically diagnosed with mild to moderate atopic dermatitis, with lesions located on both antecubital fossae, according to the Hanifin and Rajka criteria
- Investigator's Global Assessment (IGA) score of 1-3
- Eczema Area and Severity Index (EASI) score between 0.2-21
Age in the registry: 7 years to 17 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Institute of dermatology(inderm) Coordinator of this site? Confirm its status | Bangkok | Thailand | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.